
News|Videos|October 23, 2014
The Future of the Treatment of TNBC
Author(s)Sara A. Hurvitz, MD
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).
Advertisement
Clinical Pearls
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).
- BRCA-like or basal-like breast cancer that is triple-negative is particularly aggressive. Platinums may be more effective in this space.
- Many pharmaceutical companies are not looking at PARP inhibitors in large studies because of the results of 1 negative trial.
- Many TNBCs have downregulation of BRCA proteins where inhibiting PARP may be particularly effective.
- Some studies are also looking at antibodies and antibody-directed therapies to inhibit the NOTCH pathway.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















